#USA #San Diego #Aethlon Medical #Hemopurifier #Oncology Study

Aethlon Medical's Significant Developments in FY 2026

Aethlon Medical, Inc. (Nasdaq: AEMD) has announced the financial results for the fiscal year ending March 31, 2026, showcasing substantial advancements within its clinical and research frameworks. The company focuses primarily on developing unique therapeutic products designed to combat cancer and address life-threatening viral infections.

Clinical Developments

During the fiscal period, Aethlon has been making notable strides in its Australian oncology study, which recently marked the progression into its third dosing cohort. This shift signifies a pivotal milestone aimed at gathering vital data for future treatment strategies. The cohort stages are essential in assessing the Hemopurifier's efficacy in treating solid tumors. The first participant of this cohort was treated recently, completing three Hemopurifier sessions within a week.

Moreover, Aethlon is actively exploring applications for the Hemopurifier beyond oncology, venturing into areas like rheumatoid arthritis and chronic kidney disease. These expansions could significantly increase the potential market avenues for their innovative platform, which is poised to offer solutions for conditions that currently have limited treatment options.

Financial Results Overview

In terms of financial performance, Aethlon Medical reported a cash reserve of approximately $5.0 million as of March 31, 2026. This capital is intended to sustain current clinical and research projects. Additionally, the company was able to fortify its financial standing post-fiscal year by generating nearly $1.85 million through its at-the-market program.

Operating expenses exhibited a marked decline of 21.9% year-over-year, decreasing to about $7.3 million from $9.3 million. This reduction stems from disciplined financial management, resulting in substantial cuts across payroll, general administration, and professional service expenses.

The operating loss for FY 2026 was approximately $7.3 million, a decrease from the previous year's loss of $9.3 million, reflecting improved operating efficiency and disciplined expense management. Other income rose to roughly $142,000, compared to an expense of around $4 million a year prior, which affirms a positive shift in the company’s financial health.

Looking Ahead: Conference Call Details

Management will conduct a conference call to discuss these financial results and recent developments further at 4:30 PM ET today, June 10, 2026. The call will be open for questions from stakeholders, emphasizing Aethlon's commitment to transparency and investor engagement.

As Aethlon continues to enhance its Hemopurifier platform and further commercialize it across various therapies, all eyes remain on the outcomes of the ongoing studies, which may offer groundbreaking treatment paths for patients worldwide. The positive trends in both clinical and financial metrics inspire optimism for the company’s trajectory in advancing healthcare solutions that meet pressing medical needs.